Connect with us

Technology

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Published

2 years ago

on

USA News Group News Commentary 

Issued on behalf of Avant Technologies Inc.

VANCOUVER, BC, Jan. 17, 2025 /PRNewswire/ — According to experts, soon the integration of artificial intelligence (AI) into healthcare will drastically shift from a novelty, to a critical resource. With over 800 FDA-cleared health AI applications, the new expectation is that AI will be a game changer. In a new article from Fast Company, the author predicts health AI in 2025 will include home testing, AI agents, passive monitoring, ambient documentation, and autonomous coding. The World Economic Forum is also highlighting the ways generative AI could transform clinical trials. According to a new survey from eClinicalWorks, 90% of healthcare professionals report a favorable view of AI. Working to provide these powerful AI tools to the health industry are several innovators, including new developments from Avant Technologies, Inc. (OTCQB: AVAI), Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), Teladoc Health, Inc. (NYSE: TDOC), Butterfly Network, Inc. (NYSE: BFLY), and Absci Corporation (NASDAQ: ABSI).

The article continued: Analysts at market.us are predicting the Generative AI in Healthcare Market to reach US$17.2 billion by 2032, growing at a CAGR of 37% along the way. Researchers at Technavio see an even bigger future, projecting the Smart Healthcare Market (including telemedicine, mHealth, smart pills, and AI) to grow by US$125.7 billion through to 2028.

Avant Technologies and Ainnova Secure Advanced AI Algorithms for Early Detection of Four Additional Diseases in the U.S.

Avant Technologies, Inc. (OTCQB: AVAI), an emerging technology company developing solutions in artificial intelligence in healthcare, today announced its partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on revolutionizing early disease detection using AI, has acquired an exclusive license for 4 groundbreaking, AI-driven algorithms from one of Asia’s most respected and largest healthcare institutions. These solutions, validated across diverse geographies, ethnicities, and socio-economic populations with data from over 2-million patients, will join Ainnova’s existing diabetic retinopathy and retinal disease detection solutions.

The 4 algorithms include early detection for cardiovascular risk, prediabetes and type 2 diabetes, fatty liver disease, and chronic kidney disease. Combined with Ainnova’s existing retinal disease detection tools, these new algorithms will be used with Ainnova’s powerful cutting-edge AI platform, VisionAI, to detect the early markers of these diseases quickly and accurately by applying AI. 

The acquisition of an exclusive license to use 4 advanced algorithms in the Americas offers Ainova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, a robust platform for primary care providers to streamline early risk screening and improve patient care in the United States.

Ainnova will introduce these cutting-edge solutions in Latin America with strategic partners in primary healthcare services across key markets like Mexico and Brazil. AAC expects to build on Ainnova’s regional expansion by securing clearance from the U.S. Food and Drug Administration (FDA) in 2025 to then introduce these solutions in the U.S. market.

“This license represents a pivotal moment for Ainnova and for its partnership with Avant as it allows us to bring world class, validated solutions to the Americas,” said Vinicio Vargas, CEO of Ainnova. “This effort not only complements our current solutions, but it also aligns with our ongoing R&D initiatives to continue incorporating new diseases that can be detected quickly and affordably, pushing the boundaries of preventive care, and making healthcare more inclusive and accessible to all.”

CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

Other recent industry developments and happenings in the market include:

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a clinical-stage biotechnology company that recently combined with Exscientia, recently reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. REC-617 was well-tolerated across all dose levels (2-20 mg QD and 1 mg BID), with most adverse events being mild (Grade 1-2) and reversible. Notably, one patient with metastatic, platinum-resistant ovarian cancer achieved a confirmed durable partial response lasting over 6 months, while four others experienced stable disease for up to 6 months.

“These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population,” said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer, Recursion. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year.”

Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, recently announced the launch of new AI-enabled capabilities to enhance its Virtual Sitter solution to improve patient safety, address workforce challenges, and enhance care delivery for hospitals and health systems. Teladoc Health’s Virtual Sitter uses AI to allow a single remote staff member to monitor more patients, boosting inpatient team capacity by 25%. This innovation complements Teladoc’s connected care solutions, including virtual nursing, physician consults, and interpretive services, reducing administrative burdens and improving satisfaction for both clinicians and patients.

“For more than a decade, we’ve pioneered new ways for technology to support human interaction in patient care, helping hospitals and health systems transform care delivery and meet their most pressing challenges,” said Andy Puterbaugh, Teladoc Health President of Hospitals and Health Systems. “New applications of AI are now accelerating our impact, supporting continuous improvement of our fully integrated suite of connected care solutions, including Virtual Sitter.”

Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, in partnership with HeartFocus, a revolutionary, AI-enabled heart echo software by data-driven medtech company, recently announced the launch of the HeartFocus Education app. The HeartFocus Education app uses AI-powered, self-paced learning to help healthcare practitioners master 10 essential cardiac views with clinical accuracy in hours. Officially launched at ANCC MagPath 2024, the app integrates seamlessly with Butterfly iQ3 and iQ+ probes on iOS iPads, offering an intuitive, engaging, and high-impact training experience enhanced by gamification.

“HeartFocus is set to make a big impact in cardiac care, and we’re thrilled to partner with DESKi on this pioneering education platform,” said Darius Shahida, Chief Strategy Officer at Butterfly Network. “By combining our cutting-edge ultrasound technology with HeartFocus’ AI-powered training, we’re breaking down barriers to cardiac care, empowering more practitioners to learn how to deliver critical diagnostics on the spot.”

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, recently announced updates and progress across its internal pipeline of proprietary Drug Creation programs, as well as new breakthroughs demonstrated by Absci’s AI Integrated Drug Creation™ platform. Absci leadership and a series of distinguished guest speakers will be presenting on these updates today at Absci’s 2024 R&D Day.

“We are excited to showcase the target and significant opportunities we see for ABS-201, present new data for ABS-101 and ABS-301, and introduce ABS-501 to our pipeline. ABS-201, a potential treatment for male and female pattern hair loss, represents an opportunity to unlock an entirely new category of therapy for a substantial consumer-driven market with significant clinical unmet need,” said Sean McClain, Founder and CEO of Absci. “And as we near the end of 2024, we see next year as an opportunity to reach multiple milestones across our internal portfolio, and maintain a robust pipeline of potential partners across the Pharma and broader healthcare industry landscape.”

Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/

CONTACT:
USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/healthcare-ai-adoption-accelerates-as-industry-eyes-125-billion-growth-by-2028-302354611.html

Related Topics:
Continue Reading

Technology

Mission Critical Partners Announces Launch of its Justice Integration Hub in Support of the City of New Orleans

Published

1 minute ago

on

October 27, 2026

By

The $30 million ARPA-funded initiative connects public-safety and justice agencies, accelerates case processing and improves service to the community.

NEW ORLEANS, Oct. 27, 2026 /PRNewswire-PRWeb/ — Mission Critical Partners today announced the launch of its Justice Integration Hub in support of the city of New Orleans’ Justice Technology Modernization Program (JTMP). JTMP is a multiyear initiative that replaced several decades-old systems with a unified, cloud-based platform designed to improve public safety and access to justice by streamlining operations and strengthening transparency across the city and Orleans Parish criminal-justice ecosystem.

“The Justice Integration Hub is not just a technology milestone; it’s a fundamental shift in how justice is delivered,” said Darrin Reilly, president and CEO, Mission Critical Partners.

The Justice Integration Hub facilitates the seamless flow of information throughout the Parish’s complex criminal-justice ecosystem. Funded through a $30 million allocation from the American Rescue Plan Act (ARPA), JTMP represents one of the most comprehensive justice technology overhauls in the country, modernizing and transforming more than 40 years of legacy infrastructure. The program integrates the area’s entire criminal justice ecosystem — including the New Orleans Police Department, Orleans Parish Sheriff’s Office and Justice Center, District Attorney, Public Defender, Criminal District Court, and Clerk of Court — into a single, connected environment.

“The integration hub fundamentally changes how our justice agencies work together,” said Nathaniel Weaver, JTMP director. “Instead of information stopping at the boundaries between agencies, it can move securely in real time, allowing people to spend less time reentering data and more time making the decisions that move cases forward.”

From Fragmentation to Real-Time Coordination

For years, criminal-justice agencies in New Orleans and Orleans Parish operated on outdated, siloed systems that limited collaboration, slowed case processing, and created cross-department inefficiencies.

The Justice Enterprise Hub is built on Microsoft Azure and leverages a standardized enterprise data model aligned with national data-sharing models. A secure integration hub enables real-time data sharing across agencies, ensuring that critical information is accessible when and where it is needed.

Immediate Impact Across the Community

The Justice Enterprise Hub already is helping to deliver measurable improvements:

Patrol officers now have additional hours each week to spend in New Orleans communities and respond to emergencies due to more efficient digital arrest-processing workflows.Data sharing from the jail to the court facilitates automated creation of cases and scheduling of court appearances, saving approximately 6,000 hours of time clerks would spend on data entry.Faster information sharing between agencies is helping reduce hearing delays, streamline inmate transport coordination, and improve overall justice system efficiency. This significantly reduces incarceration costs and generates measurable operational savings.

A Foundation for the Future of Justice

With the core platform now fully operational, New Orleans and Orleans Parish are positioned to build on this foundation with advanced capabilities, including AI-assisted case processing, digital evidence management, and expanded state-level data integration.

“The Justice Integration Hub is not just a technology milestone; it’s a fundamental shift in how justice is delivered,” said Darrin Reilly, MCP’s president and CEO. “New Orleans and Orleans Parish now have a nation-leading, scalable, and future-ready system that enables agencies to work together more effectively and collaboratively to better serve the public. We look forward to bringing this solution to more communities across the nation.”

The system was implemented in four phases, following a competitive nationwide process that selected Mission Critical Partners and Major Services, a New Orleans-based IT consulting firm, to oversee JTMP’s development, implementation, and coordinated go-live activities across all participating agencies. Those four phases went live in succession, between November 2025 and April 2026.

About Mission Critical Partners (MCP)

Mission Critical Partners (MCP) is a leading provider of data integration, consulting, network, and cybersecurity solutions specializing in transforming mission-critical communications networks into integrated ecosystems that improve outcomes in the public-safety, justice, healthcare, transportation, and utility markets. Our comprehensive experience and vendor-agnostic approach help us develop modernized solutions that maximize value, improve efficiency, and mitigate risk. Additional information and career opportunities are available at MissionCriticalPartners.com.

Media Contact

Morgan Sava, Mission Critical Partners, 1 608-658-8858, rscarpino@pipitone.com, https://www.missioncriticalpartners.com/

View original content:https://www.prweb.com/releases/mission-critical-partners-announces-launch-of-its-justice-integration-hub-in-support-of-the-city-of-new-orleans-302920918.html

SOURCE Mission Critical Partners

Continue Reading

Technology

MadeAi Launches Dossier Expert, Bringing Agentic AI to Formulary and Value Dossier Development

Published

1 minute ago

on

October 27, 2026

By

New AI-powered solution transforms dossier creation and maintenance with source-level traceability, cross-functional collaboration, and up to 70% faster authoring and updates

CAMBRIDGE, Mass., Oct. 27, 2026 /PRNewswire-PRWeb/ — MadeAi™, a leader in AI-enabled evidence synthesis and life sciences solutions, today announced the launch of MadeAi Dossier Expert, a new AI-powered solution designed to transform how pharmaceutical and life sciences organizations create, review, and maintain formulary and value dossiers.

Traditionally, developing AMCP dossiers, global value dossiers, and health technology assessment (HTA) submissions requires months of coordination across HEOR, Clinical, Market Access, and Medical Writing teams. Evidence is dispersed across multiple sources, citations require extensive manual verification, and updates often trigger lengthy rounds of rewriting and review.

Dossier Expert replaces this fragmented process with a living, evidence-linked document that evolves as the underlying science changes.

Built to address one of the most time-consuming challenges facing Market Access and HEOR teams, Dossier Expert brings evidence management, AI-assisted authoring, citation verification, and cross-functional collaboration into a single, continuously updated environment.

From Static Documents to Living Evidence

Unlike traditional dossier authoring approaches that focus primarily on accelerating initial drafts, Dossier Expert is designed to streamline the entire dossier lifecycle—from first creation through ongoing evidence updates.

Key capabilities include:

AI-Powered Dossier Generation: Create structured AMCP, HTA, and value dossiers using customizable templates and AI-generated, evidence-grounded content.One-Click Citation Verification: Trace every AI-generated claim directly to its source document, with the supporting passage highlighted for immediate verification.Intelligent Evidence Updates: Automatically identify sections affected by changes in underlying evidence and selectively regenerate outdated content without overwriting human edits.Integrated Evidence Hub: Organize and connect indexed source materials directly to relevant dossier sections.Integrated MadeAi-LR: Access AI-enabled literature review directly for in-platform literature review support.Seamless Collaboration: Enable HEOR, Clinical, Market Access, and Medical Writing teams to work within one document, with built-in commenting, assignments, approvals, and version control.Flexible, Submission-Ready Outputs: Export approved dossiers to Word or PDF.

Accelerating Market Access Without Compromising Scientific Rigor

Dossier Expert is designed to deliver up to 70% faster dossier authoring and updates, while reducing the manual effort associated with evidence verification, document management, and recurring revisions.

“Creating a dossier is only part of the challenge. Keeping it scientifically current, fully traceable, and aligned across multiple stakeholders is where organizations lose enormous amounts of time,” said Gaugarin Oliver, Founder and CEO of MadeAi. “With Dossier Expert, we’re moving beyond AI-generated first drafts to a fundamentally different model: a living dossier that connects every claim to its evidence, identifies what needs updating, and enables experts to focus on scientific judgment rather than document administration.”

By combining AI-powered efficiency with human oversight and transparent source verification, Dossier Expert helps life sciences organizations accelerate evidence communication while maintaining the rigor required for payer and HTA engagement.

Learn more about Dossier Expert at www.madeai.com.

About MadeAi

MadeAi™ is an award-winning AI-native evidence synthesis and life sciences solutions platform designed to help pharmaceutical, biotechnology, and medical device organizations accelerate evidence generation and scientific communication. Combining advanced agentic AI capabilities with human expertise, MadeAi supports workflows across HEOR, Market Access, Medical Affairs, and RWE, delivering greater efficiency, transparency, and scientific rigor.

Media Contact

Meghan Oates-Zalesky, MadeAi, 1 617 435 2470, meghan.oates@madeai.com, www.madeai.com

View original content to download multimedia:https://www.prweb.com/releases/madeai-launches-dossier-expert-bringing-agentic-ai-to-formulary-and-value-dossier-development-302920940.html

SOURCE MadeAi

Continue Reading

Technology

Peloton Launches Peloton Broker to Streamline Early-Stage Land Acquisition for Energy Projects

Published

1 minute ago

on

October 27, 2026

By

New tract-based pre-leasing tool joins the
Land Data Management solution in the Peloton Platform

CALGARY, AB, Oct. 27, 2026 /PRNewswire/ — Peloton, a provider of energy data management software, today announced the launch of Peloton Broker, a tract-based pre-leasing management tool built for energy projects. Peloton Broker gives brokers, consultants, land departments, and legal teams one place to handle ownership discovery, negotiation tracking, and title curative work, so they can move from prospect to signed lease without re-entering data or juggling separate systems.

Peloton Broker is part of Peloton’s Land Data Management solution in the Peloton Platform, alongside LandView, LandView Map, and Peloton Dashboards. It extends Peloton’s trusted foundation to the earliest stage of land acquisition, with pre-leasing work carrying straight into agreement-based lease management in LandView.

“The pre-leasing stage has always been where land data is most scattered, with ownership research in one place, negotiation notes in another, and title issues surfacing late,” said James Hatcher, Product Manager – Land Data Management at Peloton. “Peloton Broker brings that work into the Peloton Platform from day one, so land teams start every lease with a complete picture and the rest of the organization gets land data it can trust.”

Built for the start of the lease lifecycle

Peloton Broker helps land teams at oil and gas operators and renewable energy developers:

Track ownership at the tract level, covering both surface and mineral rightsManage negotiations in integrated workflows that record every offer, contact, and status changeCatch title concerns early with title curative support, before they hold up executionWork from the map with GIS-driven prospect management connected to LandView MapKeep audit-ready records with full traceability from first contact to executed lease

Connected across the Peloton Platform

The Peloton Platform is a SaaS solution hosted by Microsoft Azure that brings well, production, and land data together in one environment. With Peloton Broker on the platform, customers get:

A single source of truth. Land, operations, and finance teams work from the same accurate, up-to-date information, with master data such as business associates, wells, and units shared across products.Linked lifecycles. Land data ties into well and production data in WellView and ProdView, and integrates with third-party ERP and financial systems.Enterprise-grade security, backed by Peloton’s SOC 1 and SOC 2 Type 2 certifications.

Peloton Broker is available now. To learn more, visit peloton.com/products/land-data-management/broker.

About Peloton

Headquartered in Calgary, Alberta, and founded in 1991, Peloton created the energy industry’s original data management solution, and it remains the standard today. With more than three decades of industry expertise and over 700 clients globally, Peloton offers software across the well, production, and land lifecycles. The Peloton Platform brings all three together in one integrated SaaS environment, hosted by Microsoft Azure.

View original content to download multimedia:https://www.prnewswire.com/news-releases/peloton-launches-peloton-broker-to-streamline-early-stage-land-acquisition-for-energy-projects-302921122.html

SOURCE Peloton Computer Enterprises Ltd.

Continue Reading

Trending